61160 Federal Register / Vol. 70, No. 202 / Thursday, October 20, 2005 / Notices 

1 15 U.S.C. 78s(b)(1). 

2 17 CFR 240.19b–4. 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated June 6, 2005 and 

published in the Federal Register on 

June 13, 2005, (70 FR 34152), 

Boehringer Ingelheim Chemicals, Inc., 

2820 N. Normandy Drive, Petersburg, 

Virginia 23805, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of Phenylacetone (8501), a 

basic class of controlled substance listed 

in Schedule II. 

The company plans to import the 

listed controlled substance to bulk 

manufacturer amphetamine. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Boehringer Ingelheim Chemicals, Inc. to 

import the basic class of controlled 

substance is consistent with the public 

interest and with United States 

obligations under international treaties, 

conventions, or protocols in effect on 

May 1, 1971, at this time. DEA has 

investigated Boehringer Ingelheim 

Chemicals, Inc. to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: October 12, 2005. 

Joseph T. Rannazzisi, 

Acting Deputy Assistant Administrator, Office 

of Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 05–20950 Filed 10–19–05; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated March 25, 2005, and 

published in the Federal Register on 

April 4, 2005, (70 FR 17124), Johnson 

Matthey, Inc., Custom Pharmaceuticals 

Department, 2003 Nolte Drive, West 

Deptford, New Jersey 08066, made 

application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

Methamphetamine (1105), a basic class 

of controlled substance listed in 

Schedule II. 

The company plans to manufacture 

the listed controlled substance in bulk 

for distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Johnson Matthey, Inc. to manufacture 

the listed basic class of controlled 

substance is consistent with the public 

interest at this time. DEA has 

investigated Johnson Matthey, Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: October 12, 2005. 

Joseph T. Rannazzisi, 

Acting Deputy Assistant Administrator, Office 

of Diversion Control, Drug Enforcement 

Administration, 

[FR Doc. 05–20949 Filed 10–19–05; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated March 25, 2005, and 

published in the Federal Register on 

April 5 2005, (70 FR 17262), Rhodes 

Technologies, 498 Washington Street, 

Coventry, Rhode Island 02816, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in Schedule I and II: 

Drug Schedule 

Tetrahydrocannabinols (7370) ..... I 

Methylphenidate (1724) ................ II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Thebaine (9333) ........................... II 

Noroxymorphone (9668) .............. II 

Drug Schedule 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for conversion and distribution to its 

customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Rhodes Technologies to manufacture 

the listed basic class of controlled 

substance is consistent with the public 

interest at this time. DEA has 

investigated Rhodes Technologies to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: October 12, 2005. 

Joseph T. Rannazzisi, 

Acting Deputy Assistant Administrator, Office 

of Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 05–20948 Filed 10–19–05; 8:45 am] 

BILLING CODE 4410–09–P 

SECURITIES AND EXCHANGE 

COMMISSION 

[Release No. 34–52598; File No. SR–Amex–

2005–098] 

Self-Regulatory Organizations; 

American Stock Exchange LLC; Notice 

of Filing and Immediate Effectiveness 

of Proposed Rule Change Relating to 

the Adoption of an Options Licensing 

Fee for the First Trust Dow Jones 

Select MicroCap Index Fund (FDM) 

October 13, 2005. 

Pursuant to Section 19(b)(1) 1 of the 

Securities Exchange Act of 1934 (the 

‘‘Act’’), and Rule 19b–4 2 thereunder, 

notice is hereby given that on 

September 29, 2005, the American Stock 

Exchange LLC (‘‘Amex’’ or ‘‘Exchange’’) 

filed with the Securities and Exchange 

Commission (‘‘Commission’’) a 

proposed rule change as described in 

Items I, II, and III below, which Items 

have been prepared by the Exchange.